ArticleMagnetic resonance imaging2008
The detection limit of a Gd3+-based T1 agent is substantially reduced when targeted to a protein microdomain.
Article in Magnetic resonance imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 58 citations in OpenAlex.
- Simple Determination of Affinity Constants of Antibodies by Competitive Immunoassays.Methods and protocols · 2024Article
- Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.International journal of molecular sciences · 2023Review
- MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022Review
- Early detection and staging of chronic liver diseases with a protein MRI contrast agent.Nature communications · 2019Article
- Methodological Aspects for Preclinical Evaluation of Gadolinium Presence in Brain Tissue: Critical Appraisal and Suggestions for Harmonization-A Joint Initiative.Investigative radiology · 2018Review
- A scale to measure MRI contrast agent sensitivity.Scientific reports · 2017Article
- Synthesis and evaluation of MR probes for targeted-reporter imaging.Chemical science · 2017Article
- Targeted delivery of gold nanoparticle contrast agents for reporting gene detection by magnetic resonance imaging.Chemical communications (Cambridge, England) · 2016Article
- Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.Angewandte Chemie (International ed. in English) · 2015Article
- Article
- Imaging free zinc levels in vivo - what can be learned?Inorganica chimica acta · 2012Article
- Noninvasive MRI of β-cell function using a Zn2+-responsive contrast agent.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Reporter protein-targeted probes for magnetic resonance imaging.Journal of the American Chemical Society · 2011Article
- Strategies for the preparation of bifunctional gadolinium(III) chelators.Current organic synthesis · 2011Article
- Molecular magnetic resonance contrast agents for the detection of cancer: past and present.Seminars in oncology · 2011Review
- MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting.Journal of the American Chemical Society · 2010Article
- A new gadolinium-based MRI zinc sensor.Journal of the American Chemical Society · 2009Article
- Responsive MRI agents for sensing metabolism in vivo.Accounts of chemical research · 2009Review
- Molecular imaging without radiopharmaceuticals?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009Article
- Polymeric PARACEST agents for enhancing MRI contrast sensitivity.Journal of the American Chemical Society · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Simple low molecular weight (MW) chelates of Gd(3+) such as those currently used in clinical MRI are considered too insensitive for most molecular imaging applications. Here, we evaluated the detection limit (DL) of a molecularly targeted low MW Gd(3+)-based T(1) agent in a model where the receptor concentration was precisely known. The data demonstrate that receptors clustered together to form a microdomain of high local concentration can be imaged successfully even when the bulk concentration of the receptor is quite low. A GdDO3A-peptide identified by phage display to target the anti-FLAG antibody was synthesized, purified and characterized. T(1-)weighted MR images were compared with the agent bound to antibody in bulk solution and with the agent bound to the antibody localized on agarose beads. Fluorescence competition binding assays show that the agent has a high binding affinity (K(D)=150 nM) for the antibody, while the fully bound relaxivity of the GdDO3A-peptide/anti-FLAG antibody in solution was a relatively modest 17 mM(-1) s(-1). The agent/antibody complex was MR silent at concentrations below approximately 9 microM but was detectable down to 4 microM bulk concentrations when presented to antibody clustered together on the surface of agarose beads. These results provided an estimate of the DLs for other T(1)-based agents with higher fully bound relaxivities or multimeric structures bound to clustered receptor molecules. The results demonstrate that the sensitivity of molecularly targeted contrast agents depends on the local microdomain concentration of the target protein and the molecular relaxivity of the bound complex. A model is presented, which predicts that for a molecularly targeted agent consisting of a single Gd(3+) complex with bound relaxivity of 100 mM(-1) s(-1) or, more reasonably, four tethered Gd(3+) complexes each having a bound relaxivity of 25 mM(-1) s(-1), the DL of a protein microdomain is approximately 690 nM at 9.4 T. These experimental and extrapolated DLs are both well below current literature estimates and suggests that detection of low MW molecularly targeted T(1) agents is not an unrealistic goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.